WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
Recent Articles
RELATED ARTICLES
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG -
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
